14-DEC-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3843 302 192 100 35 10 02/06/2019 483 193
Screened at PD     1382 142 111 64 24 7      
Pre-Screened prior to PD     2447 146 73 32 10 3      
Treatment-naive     14 14 8 4 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     520 25 15 7 2 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2046 293 143 75 25 7      
Screened at PD     1151 160 105 58 22 6      
Pre-Screened prior to PD     825 115 29 12 1 0      
Treatment-naive     14 14 8 4 1 1      
After PD on a Lung_MAP Sub-Study     56 4 1 1 1 0      
 
Sub-Study Assignments (open studies only)
S1800E     261 261 126 67 22 5      
S1900G     33 6 3 1 1 0      
S1900J     15 7 3 2 1 1      
S1900K     27 19 11 5 1 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     559 64 52 27 9 3      
Initial sub-study registrations     547 64 52 27 9 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 43 43 41 21 8 3 05/22/2025 326 103
Docetaxel plus Ramucirumab Y   23 23 22 11 4 2      
Cemiplimab plus Docetaxel and Ramucirumab Y   20 20 19 10 4 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 23 6 3 2 1 0 05/05/2023 351 115
Capmatinib + Osimertinib + Ramucirumab Y   13 5 3 2 1 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 1 0 0 11/19/2024 243 81
Amivantamab Hyaluronidase Y   3 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 16 13 7 3 0 0 08/08/2024 282 94
Tepotinib + Ramucirumab Y   10 8 3 2 0 0      
Tepotinib Y   6 5 4 1 0 0